Disposition of ampiroxicam, a prodrug of piroxicam, in man.
1. Ampiroxicam, a prodrug of the effective anti-inflammatory agent piroxicam, was completely converted to piroxicam after oral administration to man. 2. At clinical doses there was no detectable portal or systemic exposure of man to ampiroxicam, indicating that conversion to piroxicam was complete during the absorption process. 3. The pharmacokinetics of piroxicam from ampiroxicam were essentially the same as those after piroxicam itself except that Cmax was slightly lower and tmax was slightly longer after administration of ampiroxicam.
Falkner
F C
FC
Drug Metabolism Department, Pfizer, Inc., Groton, CT 06340.
Twomey
T M
TM
Borgers
A P
AP
Garg
D
D
Weidler
D
D
Gerber
N
N
Browder
I W
IW
D000375:Aging / Q000378:metabolism; D005260:Female; D005502:Food; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D008297:Male; D015394:Molecular Structure; D010894:Piroxicam / Q000493:pharmacokinetics*; D011169:Portal Vein; D011355:Prodrugs / Q000493:pharmacokinetics*; D013843:Thiazines / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*
D011355:Prodrugs; D013843:Thiazines; C065946:ampiroxicam; D010894:Piroxicam